Accordingly, our group recently developed a SOCS1-KIR mimetic, named PS-5, that significantly blocked IFN-γ-induced Jak2 and STAT1α activation, as well as expression of immunomodulatory molecules and chemokines in in vitro and ex-vivo experimental models of psoriasis [23, 24]. Here, SOCS1 is linked to psoriasis.